CEFEPIME

CEFEPIME- cefepime hydrochloride injection, powder, for solution
SAMSON MEDICAL TECHNOLOGIES LLC

1 INDICATIONS AND USAGE

1.1 Pneumonia

Cefepime is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species.

1.2 Empiric Therapy for Febrile Neutropenic Patients

Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. [see Clinical Studies (14.1) ].

1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis)

Cefepime is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria.

1.4 Uncomplicated Skin and Skin Structure Infections

Cefepime is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

1.5 Complicated Intra-abdominal Infections (used in combination with metronidazole)

Cefepime is indicated in the treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species or Bacteroides fragilis. [see Clinical Studies (14.2) ].

1.6 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection, USP and other antibacterial drugs, Cefepime for Injection, USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

2 DOSAGE AND ADMINISTRATION

THE INTENT OF THIS PHARMACY BULK PACKAGE IS FOR THE PREPARATION OF SOLUTIONS FOR INTRAVENOUS INFUSION ONLY. BEFORE ADMINISTRATION, THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION TO A CONCENTRATION OF 100 mg/mL AND FURTHER DILUTION IN 50 mL OF A COMPATIBLE SOLUTION.

THIS IS A PHARMACY BULK PACKAGE – NOT FOR DIRECT INJECTION

2.1 Dosage for Adults

Cefepime for Injection, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 500 mg dose of cefepime.

The recommended adult dosages and routes of administration are outlined Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer Cefepime for Injection, USP intravenously over approximately 30 minutes.

Table 1: Recommended Dosage Schedule for Cefepime for Injection, USP in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/minute
*or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently.**Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli.§ For P. aeruginosa , use 2 g IV every 8 hours.

Site and Type of Infection

Dose

Frequency

Duration

(days)

Adults

Intravenous (IV)

Moderate to Severe Pneumonia§

1 to 2 g IV

Every 8 to12 hours

10

Empiric therapy for febrile neutropenic patients

2 g IV

Every 8 hours

7*

Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis

0.5 to 1 g

IV/IM**

Every 12 hours

7 to 10

Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis

2 g IV

Every 12 hours

10

Moderate to Severe Uncomplicated Skin and Skin Structure Infections

2 g IV

Every 12 hours

10

Complicated Intra-abdominal Infections§ (used in combination with metronidazole)

2 g IV

Every 8 to12 hours

7 to 10

Cefepime for Injection, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 500 mg dose of cefepime.

2.2 Pediatric Patients (2 months up to 16 years)

Cefepime for Injection, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 500 mg dose of cefepime.

The maximum dose for pediatric patients should not exceed the recommended adult dose.The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is:

  • 50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).
  • For moderate to severe pneumonia due to P. aeruginosa give 50 mg per kg per dose, every 8 hours.
  • 50 mg per kg per dose, every 8 hours for febrile neutropenic patients.

2.3 Dosage Adjustments in Patients with Renal Impairment

Cefepime for Injection, Pharmacy Bulk Package bag SmartPak® should not be used in patients who require less than a 500 mg dose of cefepime.

Adult Patients

Adjust the dose of cefepime in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of cefepime should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis. The recommended doses of cefepime in patients with renal impairment are presented in Table 2.

When only serum creatinine is available, the following formula (Cockcroft and Gault equation)1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:

Males: Creatinine Clearance (mL/min) =

Weight (kg) x (140 – age)

72 × serum creatinine (mg/dL)

Females: 0.85 × above value

Table 2: Recommended Dosing Schedule for Cefepime for Injection, USP in Adult Patients With Creatinine Clearance Less Than or Equal to 60 mL/min
*
On hemodialysis days, cefepime should be administered following hemodialysis. Whenever possible, cefepime should be administered at the same time each day.

Creatinine Clearance (mL/min)

Recommended Maintenance Schedule

Greater than 60

500 mg every12 hours

1 g every12 hours

2 g every12 hours

2 g every

8 hours

30 to 60

500 mg

every 24 hours

1 g

every 24 hours

2 g

every 24 hours

2 g

every 12 hours

11 to 29

500 mg

every 24 hours

500 mg

every 24 hours

1 g

every 24 hours

2 g

every 24 hours

Less than 11

250 mg

every 24 hours

250 mg

every 24 hours

500 mg

every 24 hours

1 g

every 24 hours

Continuous Ambulatory Peritoneal Dialysis (CAPD)

500 mg

every 48 hours

1 g

every 48 hours

2 g

every 48 hours

2 g

every 48 hours

Hemodialysis *

1 g on day 1, then 500 mg every 24 hours thereafter

1 g

every 24 hours

In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), cefepime may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).

In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of cefepime for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.

Cefepime should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2).

Pediatric Patients

Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3) ], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.